(Q45072250)

English

The expression of P-glycoprotein in AML cells with FLT3 internal tandem duplications is associated with reduced apoptosis in response to FLT3 inhibitors

scientific article published in October 2004

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

9 December 2017

The expression of P-glycoprotein in AML cells with FLT3 internal tandem duplications is associated with reduced apoptosis in response to FLT3 inhibitors (English)

1 reference

Europe PubMed Central

9 December 2017

Claire Seedhouse

3

1 reference

Europe PubMed Central

9 December 2017

author name string

Hannah M Hunter

1

1 reference

Europe PubMed Central

9 December 2017

Monica Pallis

2

1 reference

Europe PubMed Central

9 December 2017

Martin Grundy

4

1 reference

Europe PubMed Central

9 December 2017

Claire Gray

5

1 reference

Europe PubMed Central

9 December 2017

Nigel H Russell

6

1 reference

Europe PubMed Central

9 December 2017

language of work or name

0 references

publication date

1 October 2004

1 reference

Europe PubMed Central

9 December 2017

British Journal of Haematology

1 reference

Europe PubMed Central

9 December 2017

127

1 reference

Europe PubMed Central

9 December 2017

26-33

1 reference

Europe PubMed Central

9 December 2017

1

1 reference

Europe PubMed Central

9 December 2017

Inhibition of FLT3 in MLL. Validation of a therapeutic target identified by gene expression based classification

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2004.05145.X

21 January 2018

Inhibitors of protein kinases: CGP 41251, a protein kinase inhibitor with potential as an anticancer agent

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2004.05145.X

21 January 2018

Multidrug resistance in cancer: role of ATP-dependent transporters

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2004.05145.X

21 January 2018

Sensitivity toward tyrosine kinase inhibitors varies between different activating mutations of the FLT3 receptor.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2004.05145.X

21 January 2018

FLT3: ITDoes matter in leukemia

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2004.05145.X

21 January 2018

A FLT3 tyrosine kinase inhibitor is selectively cytotoxic to acute myeloid leukemia blasts harboring FLT3 internal tandem duplication mutations

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2004.05145.X

21 January 2018

A FLT3-targeted tyrosine kinase inhibitor is cytotoxic to leukemia cells in vitro and in vivo

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2004.05145.X

21 January 2018

Selective apoptosis of tandemly duplicated FLT3-transformed leukemia cells by Hsp90 inhibitors

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2004.05145.X

21 January 2018

P-glycoprotein in acute myeloid leukaemia: therapeutic implications of its association with both a multidrug-resistant and an apoptosis-resistant phenotype

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2004.05145.X

21 January 2018

Human MDR 1 protein overexpression delays the apoptotic cascade in Chinese hamster ovary fibroblasts.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2004.05145.X

21 January 2018

The drug efflux protein, P-glycoprotein, additionally protects drug-resistant tumor cells from multiple forms of caspase-dependent apoptosis

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2004.05145.X

21 January 2018

Inhibition of FLT3-mediated transformation by use of a tyrosine kinase inhibitor

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2004.05145.X

21 January 2018

Inhibition of the transforming activity of FLT3 internal tandem duplication mutants from AML patients by a tyrosine kinase inhibitor

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2004.05145.X

21 January 2018

Reversal of multidrug resistance by the staurosporine derivatives CGP 41251 and CGP 42700.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2004.05145.X

21 January 2018

Inhibition of mutant FLT3 receptors in leukemia cells by the small molecule tyrosine kinase inhibitor PKC412.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2004.05145.X

21 January 2018

Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2004.05145.X

21 January 2018

In vivo treatment of mutant FLT3-transformed murine leukemia with a tyrosine kinase inhibitor

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2004.05145.X

21 January 2018

Identifiers

10.1111/J.1365-2141.2004.05145.X

1 reference

Europe PubMed Central

9 December 2017

1 reference

Europe PubMed Central

9 December 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q45072250&oldid=2064551135"